Allergy antigen and epitope thereof

Abstract

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an allergen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and food raw materials or edible processed products in which an antigen comprising such a polypeptide is eliminated or reduced, or the polypeptide is cleaved or removed. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

1 . A polypeptide specifically binding to an IgE antibody from an allergic patient, the polypeptide being any one of the following:
 (1β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 650-660;   (2β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 661-692;   (4β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 717-731;   (5β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 732-738;   (6β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 739 and 740;   (7β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 741-744;   (9β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 745-749;   (11β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 751-754;   (12β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 755;   (13β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 756-758;   (14β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 759-764;   (15β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 765 and 766;   (17β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 767;   (18β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 750 and 768-775;   (19β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 776-787;   (25β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 814 and 815;   (26β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 816-819;   (27β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 820;   (28β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 821-835;   (29β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 836-839;   (34β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 840-846;   (35β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 847-856;   (36β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 857-861;   (38β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 862-892;   (39β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 893-895;   (40β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 896-902;   (41β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 903;   (42β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 904-906;   (45β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 910-912;   (46β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 913-915;   (47β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 916-918;   (48β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 919-922;   (50β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 924-927;   (51β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 928-930;   (52β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 931-938;   (53β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 939;   (54β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 940-943; and   (55β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 944-952.   
     
     
         2 . A polypeptide specifically binding to an IgE antibody from an allergic patient, the polypeptide being any one of the following:
 (3β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 693-716;   (20β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 788-792;   (21β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 793-802;   (22β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 803-808;   (23β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 809-812;   (24β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 813;   (44β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 907-909;   (49β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 923;   (57β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 953-955;   (58β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 956-960;   (59β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 961 and 962; and   (60β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 963.   
     
     
         3 . The polypeptide according to  claim 1 , wherein the number of amino acid residues is 500 or less. 
     
     
         4 . A kit for diagnosing an allergy, comprising at least one of polypeptides according to  claim 1 . 
     
     
         5 . A composition for diagnosing an allergy, the composition comprising at least one of polypeptides according to  claim 1 , as an antigen. 
     
     
         6 . A method for providing an indicator for diagnosing an allergy in a subject, the method comprising the steps of:
 (i) contacting a sample obtained from the subject with an antigen, wherein the sample is a solution comprising an Ig antibody;   (ii) detecting binding between the IgE antibody present in the sample obtained from the subject and the antigen; and   (iii) when the binding between the IgE antibody in the subject and the antigen is detected, an indicator of the fact that the subject is allergic is provided;   wherein the antigen is at least one of polypeptides according to  claim 1 ,   
     
     
         7 . A pharmaceutical composition comprising at least one of polypeptides according to  claim 1 . 
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein the pharmaceutical composition is intended for the treatment of an allergy. 
     
     
         9 . A tester for determining the presence or absence of an antigen in an object of interest, the tester comprising an antibody that binds to at least one of polypeptides according to  claim 1 . 
     
     
         10 . A food raw material or an edible processed product in which an antigen is eliminated or reduced, or a polypeptide is cleaved or removed, wherein the antigen is at least one of polypeptides according to  claim 1 . 
     
     
         11 . A method for producing an edible processed product in which an antigen is eliminated or reduced, or a polypeptide is cleaved or removed, the method comprising the step of confirming that the antigen is eliminated or reduced, or the polypeptide is cleaved or removed, in a production process of the processed product, wherein the antigen is at least one of polypeptides according to  claim 1 . 
     
     
         12 . The polypeptide according to  claim 2 , wherein the number of amino acid residues is 500 or less. 
     
     
         13 . A kit for diagnosing an allergy, comprising at least one of polypeptides according to  claim 2 . 
     
     
         14 . A composition for diagnosing an allergy, the composition comprising at least one of polypeptides according to  claim 2  as an antigen. 
     
     
         15 . A method for providing an indicator for diagnosing an allergy in a subject, the method comprising the steps of:
 (i) contacting a sample obtained from the subject with an antigen, wherein the sample is a solution comprising an Ig antibody;   (ii) detecting binding between the IgE antibody present in the sample obtained from the subject and the antigen; and   (iii) when the binding between the IgE antibody in the subject and the antigen is detected, an indicator of the fact that the subject is allergic is provided;   wherein the antigen is at least one of polypeptides according to  claim 2 .   
     
     
         16 . A pharmaceutical composition comprising at least one of polypeptides according to  claim 2 . 
     
     
         17 . The pharmaceutical composition according to  claim 16 , wherein the pharmaceutical composition is intended for the treatment of an allergy. 
     
     
         18 . A tester for determining the presence or absence of an antigen in an object of interest, the tester comprising an antibody that binds to at least one of polypeptides according to  claim 2 . 
     
     
         19 . A food raw material or an edible processed product in which an antigen is eliminated or reduced, or a polypeptide is cleaved or removed, wherein the antigen is at least one of polypeptides according to  claim 2   
     
     
         20 . A method for producing an edible processed product in which an antigen is eliminated or reduced, or a polypeptide is cleaved or removed, the method comprising the step of confirming that the antigen is eliminated or reduced, or the polypeptide is cleaved or removed, in a production process of the processed product, wherein the antigen is at least one of polypeptides according to  claim 2 .